Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy

Clinics in Chest Medicine

Volumn 28, Issue 1, 2007, Pages 75-89

  Snow, Jennifer L ^a   Kawut, Steven M ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b College of Physicians and Surgeons Columbia University ^*  (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; INOTROPIC AGENT; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; VASODILATOR AGENT;

ANGIOCARDIOGRAPHY; CARDIOPULMONARY EXERCISE TEST; CARDIOPULMONARY HEMODYNAMICS; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG FATALITY; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EXERCISE TEST; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMIC PARAMETERS; HUMAN; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PLASMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SHORT FORM 36; SURVIVAL; TREATMENT RESPONSE; VALIDATION STUDY;

BIOLOGICAL MARKERS; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; NATRIURETIC PEPTIDE, BRAIN; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 33847663338     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.11.005     Document Type: Review

References (111)

1. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43 (2004) 48S-55S
2. Peacock A., Naeije R., Galie N., et al. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 23 (2004) 947-953
3. Kawut S.M., and Palevsky H.I. Surrogate end points for pulmonary arterial hypertension. Am Heart J 148 (2004) 559-565
4. Kawut S.M., and Palevsky H.I. New answers raise new questions in pulmonary arterial hypertension. Eur Respir J 23 (2004) 799-801
5. Rich S. The current treatment of pulmonary arterial hypertension: time to redefine success. Chest 130 (2006) 1198-1202
6. Roberts K., Preston I., and Hill N.S. Pulmonary hypertension trials: current end points are flawed, but what are the alternatives?. Chest 130 (2006) 934-936
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
8. New drug, antibiotic, and biological drug product regulations; accelerated approval; final rule. 57 FR 58958 as amended at 64 FR. 402; 1992.
9. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989) 431-440
10. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA 282 (1999) 790-795
11. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
12. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
13. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
14. Fleming T.R., Prentice R.L., Pepe M.S., et al. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 13 (1994) 955-968
15. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
16. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339 (1998) 1810-1816
17. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
18. Wittes J., Lakatos E., and Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8 (1989) 415-425
19. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
20. Oudiz R.J., Barst R.J., Hansen J.E., et al. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol 97 (2006) 123-126
21. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
22. Bucher H.C., Guyatt G.H., Cook D.J., et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 282 (1999) 771-778
23. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Aff (Millwood) 24 (2005) 67-78
24. Hoeper M.M., Markevych I., Spiekerkoetter E., et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26 (2005) 858-863
25. Lainchbury J.G., Troughton R.W., Frampton C.M., et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8 (2006) 532-538
26. Shah M.R., Claise K.A., Bowers M.T., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 150 (2005) 893-898
27. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
28. Sandoval J., Bauerle O., Palomar A., et al. Survival in primary pulmonary hypertension. Circulation 89 (1994) 1733-1744
29. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
30. Kanemoto N. Natural history of pulmonary hemodynamics in primary pulmonary hypertension. Am Heart J 114 (1987) 407-413
31. Glanville A.R., Burke C.M., Theodore J., et al. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest 91 (1987) 675-681
32. Eysmann S.B., Palevsky H.I., Reichek N., et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 80 (1989) 353-360
33. Wensel R., Opitz C.F., Anker S.D., et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 106 (2002) 319-324
34. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
35. Ewert R., Wensel R., Opitz C., et al. Prognosis in patients with primary pulmonary hypertension awaiting lung transplantation. Transplant Proc 33 (2001) 3574-3575
36. Bossone E., Paciocco G., Iarussi D., et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 121 (2002) 513-518
37. Galie N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
38. Fijalkowska A., Kurzyna M., Torbicki A., et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129 (2006) 1313-1321
39. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 167 (2003) 1433-1439
40. Williams M.H., Das C., Handler C.E., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92 (2006) 926-932
41. Mahapatra S., Nishimura R.A., Sorajja P., et al. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 47 (2006) 799-803
42. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
43. Frank H., Mlczoch J., Huber K., et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 112 (1997) 714-721
44. Raymond R.J., Hinderliter A.L., Willis P.W., et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 39 (2002) 1214-1219
45. Kawut S.M., Horn E.M., Berekashvili K.K., et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 95 (2005) 199-203
46. Kuhn K.P., Byrne D.W., Arbogast P.G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
47. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
48. Opitz C.F., Wensel R., Winkler J., et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26 (2005) 1895-1902
49. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 27 (2006) 589-595
50. Torbicki A., Kurzyna M., Kuca P., et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108 (2003) 844-848
51. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
52. Kawut S.M., Taichman D.B., Archer-Chicko C.L., et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 123 (2003) 344-350
53. Galie N., Humbert M., Vachiery J.L., et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39 (2002) 1496-1502
54. Barst R.J., McGoon M., McLaughlin V., et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 2119-2125
55. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
56. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
57. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
58. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
59. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
60. Kawut S.M., Horn E.M., Berekashvili K.K., et al. von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 128 (2005) 2355-2362
61. Lopes A.A., and Maeda N.Y. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest 114 (1998) 1276-1282
62. Veyradier A., Nishikubo T., Humbert M., et al. Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension. Circulation 102 (2000) 2460-2462
63. Nagaya N., Uematsu M., Satoh T., et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 487-492
64. Bendayan D., Shitrit D., Ygla M., et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med 97 (2003) 130-133
65. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
66. Williams M.H., Handler C.E., Akram R., et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 27 (2006) 1485-1494
67. Leuchte H.H., Holzapfel M., Baumgartner R.A., et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 43 (2004) 764-770
68. Souza R., Bogossian H.B., Humbert M., et al. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. Eur Respir J 25 (2005) 509-513
69. Souza R., Jardim C., Julio Cesar Fernandes C., et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 101 (2007) 69-75
70. Mukerjee D., Yap L.B., Holmes A.M., et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97 (2003) 1230-1236
71. Andreassen A.K., Wergeland R., Simonsen S., et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98 (2006) 525-529
72. Park M.H., Scott R.L., Uber P.A., et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. Congest Heart Fail 10 (2004) 221-225
73. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 171 (2005) 1292-1297
74. Yeo T.C., Dujardin K.S., Tei C., et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 81 (1998) 1157-1161
75. Bustamante-Labarta M., Perrone S., De La Fuente R.L., et al. Right atrial size and tricuspid regurgitation severity predict mortality or transplantation in primary pulmonary hypertension. J Am Soc Echocardiogr 15 (2002) 1160-1164
76. Forfia P.R., Fisher M.R., Mathai S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 174 (2006) 1034-1041
77. Hinderliter A.L., Willis P.W., Long W., et al. Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. Am J Cardiol 84 (1999) 481-484
78. Hinderliter A.L., Willis P.W., Barst R.J., et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 95 (1997) 1479-1486
79. Nichols K., Saouaf R., Ababneh A.A., et al. Validation of SPECT equilibrium radionuclide angiographic right ventricular parameters by cardiac magnetic resonance imaging. J Nucl Cardiol 9 (2002) 153-160
80. Saba T.S., Foster J., Cockburn M., et al. Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure. Eur Respir J 20 (2002) 1519-1524
81. Katz J., Whang J., Boxt L.M., et al. Estimation of right ventricular mass in normal subjects and in patients with primary pulmonary hypertension by nuclear magnetic resonance imaging. J Am Coll Cardiol 21 (1993) 1475-1481
82. Roeleveld R.J., Vonk-Noordegraaf A., Marcus J.T., et al. Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension. Chest 125 (2004) 572-579
83. Blyth K.G., Groenning B.A., Martin T.N., et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 26 (2005) 1993-1999
84. Boxt L.M., Katz J., Kolb T., et al. Direct quantitation of right and left ventricular volumes with nuclear magnetic resonance imaging in patients with primary pulmonary hypertension. J Am Coll Cardiol 19 (1992) 1508-1515
85. Hoeper M.M., Tongers J., Leppert A., et al. Evaluation of right ventricular performance with a right ventricular ejection fraction thermodilution catheter and MRI in patients with pulmonary hypertension. Chest 120 (2001) 502-507
86. Sciurba F., Criner G.J., Lee S.M., et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 167 (2003) 1522-1527
87. Chua R., Keogh A.M., Byth K., et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 36 (2006) 705-710
88. Deboeck G., Niset G., Vachiery J.L., et al. Physiological response to the six-minute walk test in pulmonary arterial hypertension. Eur Respir J 26 (2005) 667-672
89. Provencher S., Chemla D., Herve P., et al. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 27 (2006) 114-120
90. Miyamoto S., Nagaya N., Satoh T., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
91. Paciocco G., Martinez F.J., Bossone E., et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J 17 (2001) 647-652
92. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
93. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
94. Solway S., Brooks D., Lacasse Y., et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119 (2001) 256-270
95. Frost A.E., Langleben D., Oudiz R., et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 43 (2005) 36-39
96. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167 (2003) 211-277
97. Hansen J.E., Sun X.G., Yasunobu Y., et al. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. Chest 126 (2004) 816-824
98. Sun X.G., Hansen J.E., Oudiz R.J., et al. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation 105 (2002) 54-60
99. Sun X.G., Hansen J.E., Oudiz R.J., et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 104 (2001) 429-435
100. Rhodes J., Barst R.J., Garofano R.P., et al. Hemodynamic correlates of exercise function in patients with primary pulmonary hypertension. J Am Coll Cardiol 18 (1991) 1738-1744
101. Oudiz R.J. The role of exercise testing in the management of pulmonary arterial hypertension. Semin Respir Crit Care Med 26 (2005) 379-384
102. Yasunobu Y., Oudiz R.J., Sun X.G., et al. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest 127 (2005) 1637-1646
103. Yetman A.T., Taylor A.L., Doran A., et al. Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. Am J Cardiol 95 (2005) 697-699
104. Taichman D.B., Shin J., Hud L., et al. Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 6 (2005) 92
105. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
106. Shafazand S., Goldstein M.K., Doyle R.L., et al. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 126 (2004) 1452-1459
107. Cenedese E., Speich R., Dorschner L., et al. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 28 (2006) 808-815
108. McKenna S.P., Doughty N., Meads D.M., et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 15 (2006) 103-115
109. De Gruttola V.G., Clax P., DeMets D.L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485-502
110. Buyse M., Molenberghs G., Burzykowski T., et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1 (2000) 49-67
111. Daniels M.J., and Hughes M.D. Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16 (1997) 1965-1982